Nebot-Bral and his colleagues analyzed altered oncogenic pathways in ultramutated EC and CRC, finding that the TP53 and TGF-β pathways are inactivated whereas the WNT, PI3K and RTK/RAS pathways are activated [3], not significantly different from MMR deficient CRC/EC tumors. The gene discussed is MRC1; the disease is colorectal carcinoma.